JP2001503780A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001503780A5 JP2001503780A5 JP1998523200A JP52320098A JP2001503780A5 JP 2001503780 A5 JP2001503780 A5 JP 2001503780A5 JP 1998523200 A JP1998523200 A JP 1998523200A JP 52320098 A JP52320098 A JP 52320098A JP 2001503780 A5 JP2001503780 A5 JP 2001503780A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- recipients
- hydrochloride
- graft
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940126062 Compound A Drugs 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- SWZTYAVBMYWFGS-UHFFFAOYSA-N fingolimod hydrochloride Chemical compound Cl.CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 SWZTYAVBMYWFGS-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9624038.7A GB9624038D0 (en) | 1996-11-19 | 1996-11-19 | Organic compounds |
| GB9624038.7 | 1996-11-19 | ||
| PCT/EP1997/006408 WO1998022100A2 (en) | 1996-11-19 | 1997-11-17 | New use for 1,3-propanediol derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004152002A Division JP2004256554A (ja) | 1996-11-19 | 2004-05-21 | １，３−プロパンジオール誘導体の新しい用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001503780A JP2001503780A (ja) | 2001-03-21 |
| JP2001503780A5 true JP2001503780A5 (https=) | 2007-08-30 |
| JP4004070B2 JP4004070B2 (ja) | 2007-11-07 |
Family
ID=10803173
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52320098A Expired - Fee Related JP4004070B2 (ja) | 1996-11-19 | 1997-11-17 | １，３―プロパンジオール誘導体の新しい用途 |
| JP2004152002A Pending JP2004256554A (ja) | 1996-11-19 | 2004-05-21 | １，３−プロパンジオール誘導体の新しい用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004152002A Pending JP2004256554A (ja) | 1996-11-19 | 2004-05-21 | １，３−プロパンジオール誘導体の新しい用途 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US6274629B1 (https=) |
| EP (2) | EP0941082B1 (https=) |
| JP (2) | JP4004070B2 (https=) |
| CN (2) | CN1146411C (https=) |
| AT (2) | ATE275947T1 (https=) |
| AU (1) | AU728420B2 (https=) |
| BR (1) | BR9713105A (https=) |
| CA (1) | CA2270952C (https=) |
| CZ (1) | CZ174999A3 (https=) |
| DE (2) | DE69730727T2 (https=) |
| DK (1) | DK1312359T3 (https=) |
| ES (2) | ES2227726T3 (https=) |
| GB (1) | GB9624038D0 (https=) |
| HU (1) | HUP0000343A3 (https=) |
| ID (1) | ID21568A (https=) |
| IL (1) | IL129824A (https=) |
| NO (1) | NO992259D0 (https=) |
| NZ (1) | NZ335629A (https=) |
| PL (1) | PL190348B1 (https=) |
| PT (2) | PT941082E (https=) |
| RU (1) | RU2217136C2 (https=) |
| SI (1) | SI1312359T1 (https=) |
| SK (1) | SK284806B6 (https=) |
| WO (1) | WO1998022100A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1129066T3 (da) | 1998-11-11 | 2005-03-29 | Novartis Ag | Fremstilling af 2-amino-2-[2-(C2-20alkylphenyl)ethyl]propan-1,3-dioler |
| CN1411373A (zh) * | 1999-12-16 | 2003-04-16 | 特瓦制药工业有限公司 | 制备来氟米特的新方法和新晶形的来氟米特 |
| EP1315735A4 (en) | 2000-08-31 | 2005-04-06 | Merck & Co Inc | Phosphate derivatives as immunoregulatory compounds |
| JP4318921B2 (ja) * | 2001-02-22 | 2009-08-26 | ノバルティス アクチエンゲゼルシャフト | 移植片の機能発現遅延の処置のための医薬の製造のためのリンパ球ホーミング促進剤の使用 |
| US6995139B2 (en) * | 2001-04-20 | 2006-02-07 | Debiopharm S.A. | Cyclic undecapeptide pro-drugs and uses thereof |
| BR0209319A (pt) * | 2001-06-08 | 2004-07-20 | Novartis Ag | Tratamento ou profilaxia de rejeição de enxerto de célula produtora de insulina |
| GB0117921D0 (en) * | 2001-07-23 | 2001-09-12 | Novartis Ag | Organic compounds |
| US20040136972A1 (en) * | 2001-09-07 | 2004-07-15 | Yeda Research And Development Co. Ltd. | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
| US7780993B2 (en) * | 2001-09-07 | 2010-08-24 | Yeda Research And Development Co. Ltd. | Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts |
| GB0125443D0 (en) * | 2001-10-23 | 2001-12-12 | Novartis Ag | Organic Compounds |
| DK1471054T3 (da) | 2002-01-11 | 2009-11-09 | Daiichi Sankyo Co Ltd | Aminoalkohol-derivat eller phosphonsyre-derivat og medicinsk sammensætning, der indeholder disse |
| GB0217777D0 (en) * | 2002-07-31 | 2002-09-11 | Novartis Ag | Organic compounds |
| IL165425A0 (en) * | 2004-11-28 | 2006-01-15 | Yeda Res & Dev | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
| PE20130200A1 (es) | 2003-04-08 | 2013-03-09 | Novartis Ag | Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar |
| US7524887B2 (en) | 2003-06-06 | 2009-04-28 | Sanofi-Aventis Deutschland Gmbh | 2-amino-1,3-propanediol compounds for the treatment of acute pain |
| EP1484057A1 (en) * | 2003-06-06 | 2004-12-08 | Aventis Pharma Deutschland GmbH | Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain |
| PL1643983T3 (pl) * | 2003-06-24 | 2010-10-29 | Univ Connecticut | Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy |
| US7074659B2 (en) * | 2003-11-13 | 2006-07-11 | Volterra Semiconductor Corporation | Method of fabricating a lateral double-diffused MOSFET (LDMOS) transistor |
| NZ549162A (en) | 2004-02-24 | 2009-12-24 | Sankyo Co | Amino-pyrrol alcohol compounds |
| PL1773307T3 (pl) * | 2004-07-30 | 2015-03-31 | Novartis Ag | Preparaty 2-amino-1,3-propanodioli i ich analogów |
| BRPI0619894B8 (pt) * | 2005-12-15 | 2021-05-25 | Mitsubishi Tanabe Pharma Corp | composto de amina e composição farmacêutica |
| AR085749A1 (es) | 2011-04-01 | 2013-10-23 | Novartis Ag | Formulaciones |
| RU2496486C1 (ru) | 2012-07-11 | 2013-10-27 | Александр Васильевич Иващенко | Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение |
| US9815772B2 (en) * | 2013-03-05 | 2017-11-14 | Biocon Limited | Process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof |
| US20180250235A1 (en) | 2015-09-18 | 2018-09-06 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Fingolimod capsule composition |
| CN115477590B (zh) * | 2021-05-31 | 2023-12-12 | 上海云晟研新生物科技有限公司 | 芬戈莫德药用盐、制备方法、含其的药物组合物及应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3904679A (en) * | 1972-05-23 | 1975-09-09 | Upjohn Co | 15-Methyl and 15-ethyl prostaglandin F{HD 2{331 {0 {B analogs |
| ES2196002T3 (es) * | 1991-07-25 | 2003-12-16 | Idec Pharma Corp | Anticuerpos recombinantes para terapia humana. |
| US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| US5747034A (en) * | 1992-07-09 | 1998-05-05 | Chiron Corporation | Methods and materials for the induction of T cell anergy |
| GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| DE69321823T2 (de) * | 1992-10-21 | 1999-06-02 | Taito Co., Ltd., Tokio/Tokyo | 2-amino-1, 3- propandiolverbindung und immunosuppressium |
| WO1997024112A1 (en) * | 1995-12-28 | 1997-07-10 | Yoshitomi Pharmaceutical Industries, Ltd. | External preparation |
| JP2002241272A (ja) * | 1996-07-18 | 2002-08-28 | Mitsubishi Pharma Corp | 医薬処方組成物 |
| US6476004B1 (en) * | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
| KR20000075745A (ko) * | 1997-02-27 | 2000-12-26 | 가마후라 아키오 | 의약 조성물 |
-
1996
- 1996-11-19 GB GBGB9624038.7A patent/GB9624038D0/en active Pending
-
1997
- 1997-11-17 NZ NZ335629A patent/NZ335629A/en unknown
- 1997-11-17 AU AU54831/98A patent/AU728420B2/en not_active Ceased
- 1997-11-17 CA CA002270952A patent/CA2270952C/en not_active Expired - Fee Related
- 1997-11-17 PT PT97951219T patent/PT941082E/pt unknown
- 1997-11-17 IL IL12982497A patent/IL129824A/xx not_active IP Right Cessation
- 1997-11-17 EP EP97951219A patent/EP0941082B1/en not_active Expired - Lifetime
- 1997-11-17 US US09/308,098 patent/US6274629B1/en not_active Expired - Lifetime
- 1997-11-17 SI SI9730772T patent/SI1312359T1/sl unknown
- 1997-11-17 PT PT02025422T patent/PT1312359E/pt unknown
- 1997-11-17 JP JP52320098A patent/JP4004070B2/ja not_active Expired - Fee Related
- 1997-11-17 HU HU0000343A patent/HUP0000343A3/hu unknown
- 1997-11-17 WO PCT/EP1997/006408 patent/WO1998022100A2/en not_active Ceased
- 1997-11-17 PL PL97333463A patent/PL190348B1/pl not_active IP Right Cessation
- 1997-11-17 DK DK02025422T patent/DK1312359T3/da active
- 1997-11-17 DE DE69730727T patent/DE69730727T2/de not_active Expired - Fee Related
- 1997-11-17 CN CNB971998582A patent/CN1146411C/zh not_active Expired - Fee Related
- 1997-11-17 ES ES97951219T patent/ES2227726T3/es not_active Expired - Lifetime
- 1997-11-17 AT AT97951219T patent/ATE275947T1/de not_active IP Right Cessation
- 1997-11-17 DE DE69738033T patent/DE69738033T2/de not_active Expired - Fee Related
- 1997-11-17 SK SK659-99A patent/SK284806B6/sk unknown
- 1997-11-17 EP EP02025422A patent/EP1312359B1/en not_active Expired - Lifetime
- 1997-11-17 CN CNB2004100059961A patent/CN1293876C/zh not_active Expired - Fee Related
- 1997-11-17 CZ CZ991749A patent/CZ174999A3/cs unknown
- 1997-11-17 BR BR9713105-9A patent/BR9713105A/pt not_active Application Discontinuation
- 1997-11-17 ID IDW990370A patent/ID21568A/id unknown
- 1997-11-17 AT AT02025422T patent/ATE369846T1/de not_active IP Right Cessation
- 1997-11-17 RU RU99112577/14A patent/RU2217136C2/ru not_active IP Right Cessation
- 1997-11-17 ES ES02025422T patent/ES2289041T3/es not_active Expired - Lifetime
-
1999
- 1999-05-10 NO NO992259A patent/NO992259D0/no unknown
-
2001
- 2001-07-03 US US09/898,143 patent/US6486209B2/en not_active Expired - Fee Related
-
2002
- 2002-09-30 US US10/261,536 patent/US20030069315A1/en not_active Abandoned
-
2004
- 2004-05-21 JP JP2004152002A patent/JP2004256554A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001503780A5 (https=) | ||
| LU90956I2 (fr) | Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique | |
| AU684059B2 (en) | Application of riluzole in the treatment of Parkinson's disease and Parkinsonian syndromes | |
| GEP20043324B (en) | Purine Derivatives | |
| JP2002531505A5 (https=) | ||
| CA2304702A1 (en) | Oral compositions of levosimendan | |
| JP2002510633A5 (https=) | ||
| GEP20043383B (en) | Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds | |
| JP2002519425A5 (https=) | ||
| JP2002527474A5 (ja) | 躁病および双極性障害の治療のための医薬 | |
| BR9914631A (pt) | Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades | |
| RU2002100058A (ru) | Кристаллические производные 1-метилкарбапенема | |
| CA2321547A1 (en) | Indole derivatives and medicinal compositions containing the same | |
| JP2002522501A5 (https=) | ||
| CA2389032A1 (en) | Preventive or therapeutic agents for inflammatory diseases of intestine | |
| IL128851A (en) | Pharmaceutical composition for lowering the uric acid level in the human body | |
| CA2438509A1 (en) | Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria | |
| CA2217513A1 (en) | Pharmaceutical agents for the treatment of alzheimer's disease | |
| WO2001026641A3 (en) | Morpholinol derivatives for the treatment of obesity | |
| IE38655L (en) | Pharmaceutical compositions | |
| KR970061248A (ko) | 알츠하이머병 치료용 1, 1, 2-트리페닐부트-1-엔 유도체 | |
| CA2298493A1 (en) | Aminoethylphenoxyacetic acid derivatives and drugs for pain remission and calculi removal promotion in urinary lithiasis | |
| ATE213410T1 (de) | Diclofenac/gamma-cyclodextrin klathrat komponente | |
| WO1992017065A3 (en) | Method of inhibiting fibrosis | |
| MXPA01012936A (es) | Composicion farmaceutica que contiene sibutramina y orlistat. |